One of the strengths of this study is that it is, as far as we are aware, the first to explore the cost-effectiveness of adjuvant trastuzumab in early stage HER2+ breast cancer by heterogeneity in ER/PR subtype and age. This evidence concerns the gene ERBB2 and breast carcinoma.